Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Dow
AstraZeneca
Colorcon
McKinsey

Last Updated: May 24, 2022

NOVOLOG MIX 70/30 Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for NOVOLOG MIX 70/30

Identify potential brand extensions & biosimilar entrants

SponsorPhase
The Cleveland ClinicPhase 4
Boston Medical CenterPhase 3
Arecor LimitedPhase 1

See all NOVOLOG MIX 70/30 clinical trials

Recent Litigation for NOVOLOG MIX 70/30

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS U.S. LLC v. MYLAN N.V.2017-10-24
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.2017-03-03

See all NOVOLOG MIX 70/30 litigation

Pharmacology for NOVOLOG MIX 70/30
Established Pharmacologic ClassInsulin Analog
Chemical StructureInsulin
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NOVOLOG MIX 70/30 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NOVOLOG MIX 70/30 Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Novo Nordisk Inc. NOVOLOG MIX 70/30 insulin aspart protamine and insulin aspart Injectable Suspension 021172 See Plans and Pricing 2013-08-20 Company disclosures
Novo Nordisk Inc. NOVOLOG MIX 70/30 insulin aspart protamine and insulin aspart Injectable Suspension 021172 See Plans and Pricing 2014-04-08 Company disclosures
Novo Nordisk Inc. NOVOLOG MIX 70/30 insulin aspart protamine and insulin aspart Injectable Suspension 021172 See Plans and Pricing 2014-12-02 Company disclosures
Novo Nordisk Inc. NOVOLOG MIX 70/30 insulin aspart protamine and insulin aspart Injectable Suspension 021172 See Plans and Pricing 2013-06-21 Company disclosures
Novo Nordisk Inc. NOVOLOG MIX 70/30 insulin aspart protamine and insulin aspart Injectable Suspension 021172 See Plans and Pricing 2013-06-21 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for NOVOLOG MIX 70/30 Derived from Patent Text Search

No patents found based on company disclosures

Supplementary Protection Certificates for NOVOLOG MIX 70/30

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C00214826/01 Switzerland See Plans and Pricing FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH
132006901385693 Italy See Plans and Pricing PRODUCT NAME: SOSPENSIONE CONTENENTE INSULINA ASPART SOLUBILE E CRISTALLI DI INSULINA ASPART PROTAMINATA NEL RAPPORTO 70/30(NOVOMIX 70); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/142/017-018-019-020-021-022, 20051005
300021 Netherlands See Plans and Pricing 300021, 20140621, EXPIRES: 20150622
C300021 Netherlands See Plans and Pricing PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623
41/2005 Austria See Plans and Pricing PRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
McKesson
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.